Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
39.39B
Market cap39.39B
Price-Earnings ratio
70.10
Price-Earnings ratio70.10
Dividend yield
Dividend yield
Average volume
1.25M
Average volume1.25M
High today
$300.17
High today$300.17
Low today
$293.06
Low today$293.06
Open price
$295.95
Open price$295.95
Volume
915.90K
Volume915.90K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$250.35
52 Week low$250.35

Stock Snapshot

Alnylam Pharmaceuticals(ALNY) stock is priced at $293.50, giving the company a market capitalization of 39.39B. It carries a P/E multiple of 70.10.

During the trading session on 2026-05-09, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $300.17 and a low of $293.06. At a current price of $293.50, the stock is +0.2% higher than the low and still -2.2% under the high.

Trading activity shows a volume of 915.9K, compared to an average daily volume of 1.25M.

The stock's 52-week range extends from a low of $250.35 to a high of $495.55.

The stock's 52-week range extends from a low of $250.35 to a high of $495.55.

ALNY News

Simply Wall St 17h
Is It Time To Reconsider Alnylam Pharmaceuticals After Recent RNAi Progress And Volatile Price Moves

Wondering whether Alnylam Pharmaceuticals at around US$295.91 is offering fair value right now, or if the price is running ahead of the story? This article brea...

Is It Time To Reconsider Alnylam Pharmaceuticals After Recent RNAi Progress And Volatile Price Moves
TipRanks 4d
Alnylam Maintained at Buy as Strong TTR-Driven Momentum and Pipeline Progress Support Unchanged $510 Price Target

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, retaining the price target of $510.00. Claim 55% Off TipRanks Unlock hedg...

Simply Wall St 4d
Alnylam Pharmaceuticals Valuation After Q1 2026 Profit Breakthrough And Revenue Surge

Advertisement Q1 2026 earnings shift Alnylam’s story Alnylam Pharmaceuticals (ALNY) has just posted first quarter 2026 results that moved from a net loss to a...

Alnylam Pharmaceuticals Valuation After Q1 2026 Profit Breakthrough And Revenue Surge

Analyst ratings

69%

of 29 ratings
Buy
69%
Hold
31%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.